Claims for Patent: 12,514,899

Summary for Patent: 12,514,899

Title:	Methods of treatment using single doses of oritavancin
Abstract:	Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.
Inventor(s):	Dario Lehoux, Thomas R. Parr, Gregory Moeck, Pierre Etienne
Assignee:	Melinta Therapeutics LLC
Application Number:	US13/763,799
Patent Claims:	1. A method of treating a bacterial infection in a human subject, comprising administering a single dose of a therapeutically effective amount of a pharmaceutical composition comprising oritavancin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent, over a course of therapy to a human subject having a bacterial infection, wherein the single dose comprises at least 1200 mg oritavancin, or a pharmaceutically acceptable salt thereof, wherein the bacteria causing a bacterial infection is Streptococcus dysgalactiae, thereby treating a bacterial infection in the subject. 2. The method of claim 1, wherein the single dose comprises between 1200 mg to 1800 mg oritavancin, or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein said administering is via intravenous administration or oral administration. 4. The method of claim 1, wherein the bacterial infection is a bacterial skin infection. 5. A method of treating a bacterial infection in a human subject, comprising administering a single dose of a therapeutically effective amount of a pharmaceutical composition comprising oritavancin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent, over a course of therapy to a human subject having a bacterial infection, wherein the single dose comprises about 1200 mg oritavancin, or a pharmaceutically acceptable salt thereof, wherein the bacteria causing a bacterial infection is Streptococcus dysgalactiae, thereby treating a bacterial infection in the subject. 6. The method of claim 5, wherein said administering is via intravenous administration or oral administration. 7. The method of claim 5, wherein the bacterial infection is a bacterial skin infection.